EGFR overexpression in salivary gland carcinomas provides the rational for the investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). The activity of cetuximab in terms of clinical benefit rate (CBR) defined as the occurrence of objective response (CR or PR) or stable disease (SD) for ≥6 months was investigated. From April to December 2005, 30 patients [23 adenoid cystic carcinoma (ACC) and 7 non-ACC] were treated with cetuximab at 400 mg/m2/week followed by 250 mg/m2/week until progression, major toxicity or voluntary discontinuation. EGFR expression and gene status were retrospectively analyzed by immunocytochemistry and fluorescence in situ hybridization, respectively. A median of 14 courses of cetuximab (range 5-54) were infused. Skin toxicity was the main adverse event. Cetuximab provides a CBR in 50% (95% CL, 31 to 69%) of cases. None tumor sample showed EGFR gene amplification and an increased EGFR copy number was observed in 12% of samples, all ACC. Skin rash ≥G2, EGFR overexpression and EGFR copy number were not statistically correlated to CB. In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC.

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study / L. L. D., B. P., F.P. Perrone, P. P., C. F., M. L., C. P., M.N. Orsenigo, L. M., B. C., C. Liberatoscioli, Q. P., R.G. Calderone, S.G. Rinaldi, P. S., L.F.L. Licitra. - In: ORAL ONCOLOGY. - ISSN 1368-8375. - 45:7(2009 Jul), pp. 574-578.

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

F.P. Perrone;M.N. Orsenigo;C. Liberatoscioli;R.G. Calderone;S.G. Rinaldi;L.F.L. Licitra
2009-07

Abstract

EGFR overexpression in salivary gland carcinomas provides the rational for the investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers (RMSGCs). The activity of cetuximab in terms of clinical benefit rate (CBR) defined as the occurrence of objective response (CR or PR) or stable disease (SD) for ≥6 months was investigated. From April to December 2005, 30 patients [23 adenoid cystic carcinoma (ACC) and 7 non-ACC] were treated with cetuximab at 400 mg/m2/week followed by 250 mg/m2/week until progression, major toxicity or voluntary discontinuation. EGFR expression and gene status were retrospectively analyzed by immunocytochemistry and fluorescence in situ hybridization, respectively. A median of 14 courses of cetuximab (range 5-54) were infused. Skin toxicity was the main adverse event. Cetuximab provides a CBR in 50% (95% CL, 31 to 69%) of cases. None tumor sample showed EGFR gene amplification and an increased EGFR copy number was observed in 12% of samples, all ACC. Skin rash ≥G2, EGFR overexpression and EGFR copy number were not statistically correlated to CB. In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC.
Cetuximab; Metastatic disease; Palliative treatment; Salivary gland cancer; Target therapy; Head and neck squamous cell carcinoma
Settore MED/06 - Oncologia Medica
ORAL ONCOLOGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
PMID 18804410 Cetuximab.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 147.19 kB
Formato Adobe PDF
147.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/542204
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 146
  • ???jsp.display-item.citation.isi??? 133
social impact